Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q1 2015 · 10-Q
Revenue$42.50M$42.50M+255.2% vs Q1 2014 Net Income-$19.82M-$19.82MN/M vs Q1 2014 EPS Diluted-$0.12-$0.12N/M vs Q1 2014 Gross Profit$5,178,000+69.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flow-$13,839,000N/M Free Cash Flowderived-$13,969,000N/M Margins · derivedGross margin12.2%−13.3 pt vs Q1 2014
Operating margin-32.7%+178.0 pt vs Q1 2014
Net margin-46.6%+175.2 pt vs Q1 2014
ended Mar 31, 2015 · filed May 11, 2015 · 41 d after period end